Lupus Insight Hub

• Beeline Medicines raised $426.3M Series A to advance lupus candidates including Afimetoran (TLR7/8 inhibitor) and BLN-326 (IL-2 fusion protein)
  -...

Patients often forget specific procedures but remember how they felt during a trial. Clear explanations, patient questions answered with patience, and...

New studies reveal SLE patients face substantial extra burdens beyond core disease activity.

• Thyroid dysfunction prevalence is markedly higher in...

The Lupus Nexus registry and biorepository offers researchers access to longitudinal data, linked biospecimens, and omics from up to 3,500 lupus...

Anifrolumab shows efficacy against lupus-related autoimmune haemolytic anemia in the first reported case. This marks a potential new option for a challenging complication.

GLP-1 medications may help lupus patients by calming the immune system and reducing inflammation, potentially counteracting several damaging effects. The hypothesis remains at an early stage.

• 56% polypharmacy rate in US SLE cohort driven by antihypertensives, pain relievers, and antidepressants alongside standard therapies.
• 38%...

Orelabrutinib 75 mg delivered clear benefits in a Phase IIb trial as a potential oral targeted therapy for moderate-to-severe SLE.

• SRI-4 responses...

AbelZeta Pharma gained FDA clearance under its RMAT designation for a registrational Phase II trial of C-CAR168, a bispecific anti-CD20/BCMA CAR-T, in...

Lupus inflammatory signals reprogram neutrophils, shifting them from effective antibacterial NETosis to a weaker form after failing to sense bacterial...

Reduced serum Sestrin-1 is associated with subclinical cardiovascular risk in lupus patients, even without overt clinical disease. This connection underscores the value of early detection for heart complications in SLE.

Serum IL-32γ stands out as a novel biomarker for SLE remission, correlating with disease activity and uniquely retaining discriminatory power for stringent states like DORIS and glucocorticoid-free remission where other markers fall short.

No significant updates today.

Lupus patients require year-round sun protection as treatment guidelines now embrace treat-to-target for real remission, enabling warriors to thrive rather than just survive.

A UCLA team led by Lili Yang received a $7.49 million CIRM grant to develop a universal CAR-NKT cell therapy targeting MS. Key advantages include dual...

Reduced C3 levels directly connect dyslipidemia to renal involvement in lupus, underscoring complement activation as a driver of lupus nephritis progression.

Skin manifestations often serve as the first visible signs of systemic autoimmune diseases like lupus. Recognizing patterns such as photosensitive...

New research from the University of Toronto Lupus Clinic identifies three arthritis subtypes in SLE: non-deforming arthritis (NDA) and Jaccoud’s...

Resveratrol increases FcγRIIB expression on B cells, reducing autoantibody titers and plasma cells in lupus-prone mice via Sirt1 and NF-κB pathways. This mechanism could counter autoimmune diseases like SLE triggered by COVID or spike exposure.

Clinical Research Advances

• 🔥 5-Protein Panel for SLE Diagnosis: A cost-optimized 5-protein panel (TRIM21, SOD2, KLK3, IL15, ADIPOQ) achieved...